The Cleveland Clinic Innovation Accelerator

克利夫兰诊所创新加速器

• 批准号: 8573640
• 负责人: PAUL E DICORLETO
• 金额: $ 110.62万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-26 至 2020-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8573640
• 关键词: Address; Area; Back; Cardiovascular system; Clinic; Clinical; Complement; Development; Devices; Diagnostic; Funding; Generations; Goals; Health; Human; Institutes; Institution; Laboratories; Medical center; Mentors; Mission; National Heart, Lung, and Blood Institute; Occupations; Ohio; Patient Care; Pediatric Hospitals; Peer Review; Research; Research Personnel; Resources; Solutions; Staging; Technology; Therapeutic; Training; Translating; Universities; Validation; abstracting; arm; base; commercialization; experience; improved; innovation; pre-clinical; programs; success; tool

DESCRIPTION (provided by applicant): Cleveland Clinic (CC) and its partners Case Western Reserve University, Cincinnati Children's Hospital Medical Center, The Ohio State University and University of Cincinnati have a longstanding commitment and documented success in transitioning laboratory and clinical innovations into dramatic improvements in patient care, CC alone, via its commercialization arm CC Innovations (CCI), has generated 53 spin-off companies and $644 million in equity financing in the past decade; however CCI has a focus on more mature programs and does not reach back into the research pipeline. Also, contributing to commercialization success of the applicant institutions has been the establishment of the state-funded Global Cardiovascular Innovation Center (GCIC) that has a mission of advancing late-stage cardiovascular innovations, i.e., "shovel ready" opportunities with rapid job creation potential. The applicant consortium has now come together to address an unmet need by proposing a new Center (Cleveland Clinic Innovation Accelerator, CCIA) with an overall goal of propelling early-stage projects forward and educating researchers to be full partners in transforming their discoveries into high-impact advances in patient care. The proposed Center will enhance and coordinate the existing resources of the five partnering institutions to advance the very strong pipeline of laboratory discoveries and technical innovations generated every year in NHLBI mission areas (over 250 NHLBI-funded projects). This application has three specifics aims: (1) To create the CCIA - a self sustainable, multi-institutional consortium focused on translating early innovations in NHLBI mission areas into advanced solutions for improving global patient care. CCIA will complement the mission of the GCIC by reaching earlier into the discovery and development pipeline in order to address the gap between discovery research and validation/pre-clinical development. (2) To select through rigorous peer-review commercially promising NHLBI funded projects that will receive funds and expert project management. Projects shall span the technology range of diagnostics, devices, therapeutics and tools. (3) To create a nationally accessible institute for educating and mentoring researchers, clinicians and developers in biomedical innovation and entrepreneurism. The Center will provide experience-based training to cultivate a growing cadre of commercially successful innovators. Generation of the CCIA will thus create a self-sustainable engine for propelling a large pipeline of NHLBI-related research discoveries into advances in human health. (End of Abstract)

描述（由申请人提供）： 克利夫兰诊所（CC）及其合作伙伴凯斯西储大学，辛辛那提儿童医院医疗中心，俄亥俄州州立大学和辛辛那提大学在将实验室和临床创新转化为患者护理的显着改善方面有着长期的承诺和成功的记录，仅CC一家，通过其商业化部门CC创新（CCI），在过去的十年中，CCI已经产生了53家分拆公司和6.44亿美元的股权融资;然而，CCI专注于更成熟的项目，并没有回到研究管道中。此外，国家资助的全球心血管创新中心（GCIC）的建立也为申请机构的商业化成功做出了贡献，该中心的使命是推进晚期心血管创新，即，具有快速创造就业机会潜力的“铲式”机会。申请人联盟现在已经走到一起，通过提出一个新的中心（克利夫兰诊所创新加速器，CCIA）来解决未满足的需求，其总体目标是推动早期项目向前发展，并教育研究人员成为将其发现转化为患者护理高影响力进步的全面合作伙伴。拟议的中心将加强和协调五个合作机构的现有资源，以推进每年在NHLBI使命领域产生的非常强大的实验室发现和技术创新管道（超过250个NHLBI资助的项目）。该申请有三个具体目标：（1）创建CCIA -一个自我可持续的多机构联盟，专注于将NHLBI使命领域的早期创新转化为改善全球患者护理的先进解决方案。CCIA将通过更早地进入发现和开发管道来补充GCIC的使命，以解决发现研究与验证/临床前开发之间的差距。(2)通过严格的同行评审选择有商业前景的NHLBI资助项目，这些项目将获得资金和专家项目管理。项目应涵盖诊断、设备、治疗和工具的技术范围。(3)创建一个全国性的研究所，用于教育和指导研究人员，临床医生和生物医学创新和生物医学开发人员。该中心将提供基于经验的培训，以培养越来越多的商业上成功的创新者。因此，CCIA的产生将创造一个自我可持续的引擎，将NHLBI相关研究发现的大量管道推进人类健康的进步。 (End摘要）